We suggest you to use Clal Biotechnology fundamental analysis to see if markets are presently mispricing the company. In plain English you can use it to find out if Clal Biotechnology is indeed mispriced or if you can make any profits on it by purchasing it and then waiting for the market to recognize its mistake and reprise the security. . We found thirty available fundamental indicators for Clal Biotechnology Industries Ltd which can be compared to its rivals. To make sure the equity is not overpriced, please confirm all Clal Biotechnology fundamentals including its Current Valuation, Gross Profit, Debt to Equity, as well as the relationship between Price to Book and Cash and Equivalents . Use Clal Biotechnology to protect your portfolios against small markets fluctuations. The stock experiences normal downward trend and little activity. Check odds of Clal Biotechnology to be traded at S284.82 in 30 days.
Clal Biotechnology Company Summary
Clal Biotechnology competes with Kamada Ltd, Compugen Ltd, BioTime, Pluristem Therapeutics, and Protalix BioTherapeutics. Clal Biotechnology Industries Ltd. is a private equity and venture capital firm specializing in development stage, pre-clinical incubation, seed, start-up, early venture, emerging growth, mid venture, late venture, PIPEs, and growth capital stages of financing. It operates as a subsidiary of Clal Industries and Investments Ltd. Clal Biotechnology operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange.
Clal Biotechnology Operating Margin vs Current Ratio
Clal Biotechnology Industries Ltd is rated below average in operating margin category among related companies. It is rated fifth in current ratio category among related companies .
|Operating Margin ( % )|
|Current Ratio ( times )|
Clal Biotechnology Systematic Risk